NeuroSense Therapeutics Announces Promising Phase 2b PARADIGM Study Results Showing Significant Survival Advantage for ALS Drug PrimeC
Reuters
Sep 04, 2025
NeuroSense <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Promising Phase 2b PARADIGM Study Results Showing Significant Survival Advantage for ALS Drug PrimeC
NeuroSense Therapeutics Ltd. has announced additional clinical data from its Phase 2b PARADIGM Study, focusing on the treatment of ALS with its drug PrimeC. The study, conducted over three years with the largest site in Israel enrolling 44 patients, revealed a significant survival advantage for those treated with PrimeC compared to the placebo group. Specifically, 50% of participants initially randomized to PrimeC remain alive, compared to approximately 7% in the placebo group. These results, which have already been presented, underscore PrimeC's potential to extend survival in ALS patients, with statistical significance achieved (p=0.007). The company continues to analyze long-term data to support regulatory submissions, particularly with Health Canada, as part of its ongoing global development strategy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-084296), on September 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.